|
1
|
International Agency for Research on
Cancer (IARC): WHO Classification of Tumours of Soft Tissue and
Bone. Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F: 5. 4th
edition. IARC; Lyon: 2013
|
|
2
|
Heck RK Jr, Peabody TD and Simon MA:
Staging of primary malignancies of bone. CA Cancer J Clin.
56:366–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chow WA: Update on chondrosarcomas. Curr
Opin Oncol. 19:371–376. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsuda Y, Ogura K, Hakozaki M, Kikuta K, Ae
K, Tsuchiya H, Iwata S, Ueda T, Kawano H and Kawai A: Mesenchymal
chon-drosarcoma: A Japanese Musculoskeletal Oncology Group (JMOG)
study on 57 patients. J Surg Oncol. 115:760–767. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Theocharis AD, Manou D and Karamanos NK:
The extracellular matrix as a multitasking player in disease. FEBS
J. 286:2830–2869. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nikitovic D, Papoutsidakis A, Karamanos NK
and Tzanakakis GN: Lumican affects tumor cell functions, tumor-ECM
interactions, angiogenesis and inflammatory response. Matrix Biol.
35:206–214. 2014. View Article : Google Scholar
|
|
7
|
Varol C and Sagi I:
Phagocyte-extracellular matrix crosstalk empowers tumor development
and dissemination. FEBS J. 285:734–751. 2018. View Article : Google Scholar
|
|
8
|
Yuzhalin AE, Lim SY, Kutikhin AG and
Gordon-Weeks AN: Dynamic matrisome: ECM remodeling factors
licensing cancer progression and metastasis. Biochim Biophys Acta
Rev Cancer. 1870:207–228. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neill T, Schaefer L and Iozzo RV: Decoding
the Matrix: Instructive Roles of Proteoglycan Receptors.
Biochemistry. 54:4583–4598. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Karamanou K, Perrot G, Maquart FX and
Brézillon S: Lumican as a multivalent effector in wound healing.
Adv Drug Deliv Rev. 129:344–351. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nikitovic D, Aggelidakis J, Young MF,
Iozzo RV, Karamanos NK and Tzanakakis GN: The biology of small
leucine-rich proteoglycans in bone pathophysiology. J Biol Chem.
287:33926–33933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen S and Birk DE: The regulatory roles
of small leucine-rich proteoglycans in extracellular matrix
assembly. FEBS J. 280:2120–2137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schaefer L and Iozzo RV: Biological
functions of the small leucine-rich proteoglycans: From genetics to
signal transduction. J Biol Chem. 283:21305–21309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Merline R, Schaefer RM and Schaefer L: The
matricellular functions of small leucine-rich proteoglycans
(SLRPs). J Cell Commun Signal. 3:323–335. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grogan SP, Chen X, Sovani S, Taniguchi N,
Colwell CW Jr, Lotz MK and D'Lima DD: Influence of cartilage
extracellular matrix molecules on cell phenotype and neocartilage
formation. Tissue Eng Part A. 20:264–274. 2014. View Article : Google Scholar :
|
|
17
|
Lewis JL, Krawczak DA, Oegema TR Jr and
Westendorf JJ: Effect of decorin and dermatan sulfate on the
mechanical properties of a neocartilage. Connect Tissue Res.
51:159–170. 2010. View Article : Google Scholar
|
|
18
|
Burdan F, Szumiło J, Korobowicz A,
Farooquee R, Patel S, Patel A, Dave A, Szumiło M, Solecki M,
Klepacz R, et al: Morphology and physiology of the epiphyseal
growth plate. Folia Histochem Cytobiol. 47:5–16. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Melrose J, Shu C, Whitelock JM and Lord
MS: The cartilage extracellular matrix as a transient developmental
scaffold for growth plate maturation. Matrix Biol. 52-54:363–383.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Appunni S, Anand V, Khandelwal M, Gupta N,
Rubens M and Sharma A: Small Leucine Rich Proteoglycans (decorin,
biglycan and lumican) in cancer. Clin Chim Acta. 491:1–7. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu L, Li Z, Liu SY, Xu SY and Ni GX:
Asporin and osteoarthritis. Osteoarthritis Cartilage. 23:933–939.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ni GX, Li Z and Zhou YZ: The role of small
leucine-rich proteoglycans in osteoarthritis pathogenesis.
Osteoarthritis Cartilage. 22:896–903. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Söderström M, Böhling T, Ekfors T,
Nelimarkka L, Aro HT and Vuorio E: Molecular profiling of human
chondrosarcomas for matrix production and cancer markers. Int J
Cancer. 100:144–151. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chansky H, Robbins JR, Cha S, Raskind WH,
Conrad EU and Sandell LJ: Expression of cartilage extracellular
matrix and potential regulatory genes in a new human chondrosarcoma
cell line. J Orthop Res. 16:521–530. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nikitovic D, Chalkiadaki G, Berdiaki A,
Aggelidakis J, Katonis P, Karamanos NK and Tzanakakis GN: Lumican
regulates osteosarcoma cell adhesion by modulating TGFβ2 activity.
Int J Biochem Cell Biol. 43:928–935. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Berdiaki A, Datsis G, Nikitovic D,
Tsatsakis A, Katonis P, Karamanos N and Tzanakakis G: Parathyroid
hormone (PTH) peptides through the regulation of hyaluronan
metabolism affect osteosarcoma cell migration. IUBMB Life.
62:377–386. 2010.PubMed/NCBI
|
|
27
|
Voudouri K, Nikitovic D, Berdiaki A,
Kletsas D, Karamanos NK and Tzanakakis GN: IGF-I/EGF and E2
signaling crosstalk through IGF-IR conduit point affects breast
cancer cell adhesion. Matrix Biol. 56:95–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Im GI, Jung NH and Tae SK: Chondrogenic
differentiation of mesenchymal stem cells isolated from patients in
late adulthood: The optimal conditions of growth factors. Tissue
Eng. 12:527–536. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khaghani SAB, Akbarova G, Soon CF and
Dilbazi G: Effect of transforming growth factor-β2 on biological
regulation of multilayer primary chondrocyte culture. Cell Tissue
Bank. 19:763–775. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boumédiene K, Takigawa M and Pujol JP:
Cell density-dependent proliferative effects of transforming growth
factor (TGF)-β 1, β 2, and β 3 in human chondrosarcoma cells
HCS-2/8 are associated with changes in the expression of TGF-β
receptor type I. Cancer Invest. 19:475–486. 2001. View Article : Google Scholar
|
|
31
|
Boeuf S, Bovée JV, Lehner B, van den Akker
B, van Ruler M, Cleton-Jansen AM and Richter W: BMP and TGFbeta
pathways in human central chondrosarcoma: Enhanced endoglin and
Smad 1 signaling in high grade tumors. BMC Cancer. 12:4882012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Luca F: Regulatory Role for Growth
Hormone in Statural Growth: IGF-Dependent and IGF-Independent
Effects on Growth Plate Chondrogenesis and Longitudinal Bone
Growth. Pediatr Endocrinol Rev. 16(Suppl 1): 33–38. 2018.PubMed/NCBI
|
|
33
|
Hiraoka K, Zenmyo M, Komiya S, Kawabata R,
Yokouchi M, Suzuki R, Hamada T, Kato S and Nagata K: Relationship
of p21 (waf1/cip1) and differentiation in chondrosarcoma cells.
Virchows Arch. 440:285–290. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mytilinaiou M, Nikitovic D, Berdiaki A,
Papoutsidakis A, Papachristou DJ, Tsatsakis A and Tzanakakis GN:
IGF-I regulates HT1080 fibrosarcoma cell migration through a
syndecan-2/Erk/ezrin signaling axis. Exp Cell Res. 361:9–18. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nikitovic D, Berdiaki A, Zafiropoulos A,
Katonis P, Tsatsakis A, Karamanos NK and Tzanakakis GN: Lumican
expression is positively correlated with the differentiation and
negatively with the growth of human osteosarcoma cells. FEBS J.
275:350–361. 2008. View Article : Google Scholar
|
|
36
|
Coulson-Thomas VJ, Coulson-Thomas YM,
Gesteira TF, Andrade de Paula CA, Carneiro CR, Ortiz V, Toma L, Kao
WW and Nader HB: Lumican expression, localization and antitumor
activity in prostate cancer. Exp Cell Res. 319:967–981. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mao W, Luo M, Huang X, Wang Q, Fan J, Gao
L, Zhang Y and Geng J: Knockdown of lumican inhibits proliferation
and migration of bladder cancer. Transl Oncol. 12:1072–1078. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen L, Zhang Y, Zuo Y, Ma F and Song H:
Lumican expression in gastric cancer and its association with
biological behavior and prognosis. Oncol Lett. 14:5235–5240.
2017.PubMed/NCBI
|
|
39
|
Hsiao KC, Chu PY, Chang GC and Liu KJ:
Elevated Expression of Lumican in Lung Cancer Cells Promotes Bone
Metastasis through an Autocrine Regulatory Mechanism. Cancers
(Basel). 12:2332020. View Article : Google Scholar
|
|
40
|
Yang CT, Hsu PC and Chow SE:
Downregulation of lumican enhanced mitotic defects and aneuploidy
in lung cancer cells. Cell Cycle. 19:97–108. 2020. View Article : Google Scholar
|
|
41
|
Chen X, Li X, Hu X, Jiang F, Shen Y, Xu R,
Wu L, Wei P and Shen X: LUM Expression and Its Prognostic
Significance in Gastric Cancer. Front Oncol. 10:6052020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Karamanou K, Franchi M, Piperigkou Z,
Perreau C, Maquart FX, Vynios DH and Brézillon S: Lumican
effectively regulates the estrogen receptors-associated functional
properties of breast cancer cells, expression of matrix effectors
and epithelial-to-mesenchymal transition. Sci Rep. 7:451382017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jeanne A, Untereiner V, Perreau C, Proult
I, Gobinet C, Boulagnon-Rombi C, Terryn C, Martiny L, Brézillon S
and Dedieu S: Lumican delays melanoma growth in mice and drives
tumor molecular assembly as well as response to matrix-targeted
TAX2 therapeutic peptide. Sci Rep. 7:77002017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rahimi RA and Leof EB: TGF-β signaling: A
tale of two responses. J Cell Biochem. 102:593–608. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Herpin A and Cunningham C: Cross-talk
between the bone morphogenetic protein pathway and other major
signaling pathways results in tightly regulated cell-specific
outcomes. FEBS J. 274:2977–2985. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Iozzo RV, Buraschi S, Genua M, Xu SQ,
Solomides CC, Peiper SC, Gomella LG, Owens RC and Morrione A:
Decorin antagonizes IGF receptor I (IGF-IR) function by interfering
with IGF-IR activity and attenuating downstream signaling. J Biol
Chem. 286:34712–34721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Baker J, Liu JP, Robertson EJ and
Efstratiadis A: Role of insulin-like growth factors in embryonic
and postnatal growth. Cell. 75:73–82. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu JP, Baker J, Perkins AS, Robertson EJ
and Efstratiadis A: Mice carrying null mutations of the genes
encoding insulin-like growth factor I (Igf-1) and type 1 IGF
receptor (Igf1r). Cell. 75:59–72. 1993.PubMed/NCBI
|
|
49
|
Vlahovic G, Meadows KL, Hatch AJ, Jia J,
Nixon AB, Uronis HE, Morse MA, Selim MA, Crawford J, Riedel RF, et
al: A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in
Combination with Everolimus (RAD001) and Panitumumab in Patients
with Advanced Cancer. Oncologist. 23:782–790. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Peterse EF, Cleven AH, De Jong Y,
Briaire-de Bruijn I, Fletcher JA, Danen EH, Cleton-Jansen AM and
Bovée JV: No preclinical rationale for IGF1R directed therapy in
chondro-sarcoma of bone. BMC Cancer. 16:4752016. View Article : Google Scholar
|
|
51
|
Schönherr E, Sunderkötter C, Iozzo RV and
Schaefer L: Decorin, a novel player in the insulin-like growth
factor system. J Biol Chem. 280:15767–15772. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Aggelidakis J, Berdiaki A, Nikitovic D,
Papoutsidakis A, Papachristou DJ, Tsatsakis AM and Tzanakakis GN:
Biglycan regulates MG63 osteosarcoma cell growth through a LPR6/
β-catenin/IGFR-IR signaling axis. Front Oncol. 8:4702018.
View Article : Google Scholar
|
|
53
|
Matsumura T, Whelan MC, Li XQ and Trippel
SB: Regulation by IGF-I and TGF-beta1 of Swarm-rat chondrosarcoma
chon-drocytes. J Orthop Res. 18:351–355. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Metalli D, Lovat F, Tripodi F, Genua M, Xu
SQ, Spinelli M, Alberghina L, Vanoni M, Baffa R, Gomella LG, et al:
The insulin-like growth factor receptor I promotes motility and
invasion of bladder cancer cells through Akt- and mitogen-activated
protein kinase-dependent activation of paxillin. Am J Pathol.
176:2997–3006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cantini G, Lombardi A, Piscitelli E, Poli
G, Ceni E, Marchiani S, Ercolino T, Galli A, Serio M, Mannelli M,
et al: Rosiglitazone inhibits adrenocortical cancer cell
proliferation by interfering with the IGF-IR intracellular
signaling. PPAR Res. 2008:9040412008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Qin J, Shaukat I, Mainard D, Netter P,
Barré L and Ouzzine M: Constitutive activation of EGFR is
associated with tumor progression and plays a prominent role in
malignant phenotype of chondrosarcoma. Oncotarget. 10:3166–3182.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kamemura N, Murakami S, Komatsu H, Sawanoi
M, Miyamoto K, Ishidoh K, Kishimoto K, Tsuji A and Yuasa K: Type II
cGMP-dependent protein kinase negatively regulates fibroblast
growth factor signaling by phosphorylating Raf-1 at serine 43 in
rat chondrosarcoma cells. Biochem Biophys Res Commun. 483:82–87.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Guan PP, Yu X, Guo JJ, Wang Y, Wang T, Li
JY, Konstantopoulos K, Wang ZY and Wang P: By activating matrix
metalloproteinase-7, shear stress promotes chondrosarcoma cell
motility, invasion and lung colonization. Oncotarget. 6:9140–9159.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lee KS, Kim SW and Lee HS: Orostachys
japonicus induce p53-dependent cell cycle arrest through the MAPK
signaling pathway in OVCAR-3 human ovarian cancer cells. Food Sci
Nutr. 6:2395–2401. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Boroumand Moghaddam A, Moniri M, Azizi S,
Abdul Rahim R, Bin Ariff A, Navaderi M and Mohamad R: Eco-Friendly
Formulated Zinc Oxide Nanoparticles: Induction of Cell Cycle Arrest
and Apoptosis in the MCF-7 Cancer Cell Line. Genes (Basel).
8:2812017. View Article : Google Scholar
|
|
61
|
Dai X, Ma W, He X and Jha RK: Review of
therapeutic strategies for osteosarcoma, chondrosarcoma, and
Ewing's sarcoma. Med Sci Monit. 17:RA177–RA190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mery B, Espenel S, Guy JB, Rancoule C,
Vallard A, Aloy MT, Rodriguez-Lafrasse C and Magné N: Biological
aspects of chon-drosarcoma: Leaps and hurdles. Crit Rev Oncol
Hematol. 126:32–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Philippou A, Christopoulos PF and
Koutsilieris DM: Clinical studies in humans targeting the various
components of the IGF system show lack of efficacy in the treatment
of cancer. Mutat Res Rev Mutat Res. 772:105–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fiedler LR, Schönherr E, Waddington R,
Niland S, Seidler DG, Aeschlimann D and Eble JA: Decorin regulates
endothelial cell motility on collagen I through activation of
insulin-like growth factor I receptor and modulation of α2β1
integrin activity. J Biol Chem. 283:17406–17415. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Santra M, Eichstetter I and Iozzo RV: An
anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to
growth suppression and cytodifferentiation of mammary carcinoma
cells. J Biol Chem. 275:35153–35161. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang W, Ge Y, Cheng Q, Zhang Q, Fang L
and Zheng J: Decorin is a pivotal effector in the extracellular
matrix and tumour micro-environment. Oncotarget. 9:5480–5491. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Xing X, Gu X and Ma T: Knockdown of
biglycan expression by RNA interference inhibits the proliferation
and invasion of, and induces apoptosis in, the HCT116 colon cancer
cell line. Mol Med Rep. 12:7538–7544. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Schaefer L, Tredup C, Gubbiotti MA and
Iozzo RV: Proteoglycan neofunctions: Regulation of inflammation and
autophagy in cancer biology. FEBS J. 284:10–26. 2017. View Article : Google Scholar :
|
|
69
|
Liu B, Xu T, Xu X, Cui Y and Xing X:
Biglycan promotes the chemotherapy resistance of colon cancer by
activating NF-κB signal transduction. Mol Cell Biochem.
449:285–294. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Schulz GB, Grimm T, Sers C, Riemer P,
Elmasry M, Kirchner T, Stief CG, Karl A and Horst D: Prognostic
value and association with epithelial-mesenchymal transition and
molecular subtypes of the proteoglycan biglycan in advanced bladder
cancer. Urol Oncol. 37:530.e9–530.e18. 2019. View Article : Google Scholar
|
